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Background: Ras is a membrane-associated small G-protein that funnels growth and differentiation signals into
downstream signal transduction pathways by cycling between an inactive, GDP-bound and an active, GTP-bound
state. Aberrant Ras activity as a result of oncogenic mutations causes de novo cell transformation and promotes
tumor growth and progression.
Results: Here, we describe a novel strategy to block deregulated Ras activity by means of oligomerized
cognate protein modules derived from the Ras-binding domain of c-Raf (RBD), which we named MSOR for
multivalent scavengers of oncogenic Ras. The introduction of well-characterized mutations into RBD was
used to adjust the affinity and hence the blocking potency of MSOR towards activated Ras. MSOR inhibited
several oncogenic Ras-stimulated processes including downstream activation of Erk1/2, induction of matrix-
degrading enzymes, cell motility and invasiveness in a graded fashion depending on the oligomerization
grade and the nature of the individual RBD-modules. The amenability to accurate experimental regulation
was further improved by engineering an inducible MSOR-expression system to render the reversal of
oncogenic Ras effects controllable.
Conclusion: MSOR represent a new tool for the experimental and possibly therapeutic selective blockade
of oncogenic Ras signals.
Keywords: Cellular transformation, Ras, RBD, Tet-off system, MSOR: multivalent scavengers of oncogenic RasBackground
The prototypical Ras isoforms H-Ras, K-Ras and N-
Ras (collectively Ras) are membrane-associated small
G-proteins that cycle between an active, GTP-bound
and an inactive, GDP-bound state. Ras becomes activated,
that is GTP-loaded, by guanine nucleotide exchange fac-
tors (GEFs) such as Sos or RasGRP, which are themselves
engaged and activated downstream of various cell surface
receptors via adapter proteins, like Shc and Grb-2 and/or
via second messenger lipids like phosphatidic acid or diac-
ylglycerol [1,2]. Inactivation of GTP-loaded Ras occurs
through a GTP-hydrolase (GTPase) activity intrinsic to
Ras and enhancement of this reaction by GTPase activat-
ing proteins (GAPs) [1,3]. Ras function is also controlled
by a series of obligatory post-translational modifications* Correspondence: Martin.Augsten@ki.se
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stated.which include an initial farnesylation step and the revers-
ible attachment of palmitate groups to N-Ras and H-Ras
[4]. Although many details of this complex processing re-
main unknown, it is well established that the correct post-
translational processing is required to direct Ras to
cellular membranes and specific microdomains within the
plasma membrane (PM) [5].
Ras proteins play important roles in receptor-mediated
signal transduction pathways that control cell proliferation
and differentiation and are moreover critically involved in
the regulation of cell motility and invasiveness [3,6,7]. Ras
regulates these processes by feeding signals into various
major signaling pathways, prominently the Erk kinase path-
way, a cascade of protein kinases which ultimately drives
the transcription of key target genes for cell cycle progres-
sion and other processes [8]. Ras-dependent activation of
the Erk kinase pathway relies on the productive contact of
Ras-GTP with members of the Raf family of serine/threo-
nine kinases (collectively Raf), which together with other
coincident inputs result in Raf activation [9,10]. Raf bindsl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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(RBD), roughly 80 amino acid residues in size, that features
several orders of magnitude higher affinity for Ras-GTP
than Ras-GDP [11,12]. Several amino acid residues in the
RBD are critical for the interaction with Ras-GTP and mu-
tation of these sites impairs the high affinity binding of
RBD to Ras-GTP [13,14].
Tight regulation of the Ras activation status is critical
for cell physiology. Mutations that convert Ras into an
oncoprotein are found in up to 25% of human tumors [15]
(www.sanger.ac.uk). Oncogenic mutations, including sub-
stitutions of glycine 12 and glutamine 61, compromise the
intrinsic and GAP-promoted GTPase activity of Ras. In
agreement with a critical role of continuous aberrant Ras-
GTP elicited signaling in oncogenesis, defects in GAP
function or gain-of-function mutations in GEFs do also re-
sult in cell transformation and other pathological condi-
tions [1,16-18]. Aberrant activation of the Ras/Raf-pathway
contributes to essential aspects of tumor development and
progression such as cell cycle deregulation, avoidance of
apoptosis, cell motility and drug resistance and are more-
over known to be important for tumor maintenance and
cancer cell viability at late stages of tumorogenesis [19,20].
Due to its nodal role in cell transformation, Ras was early
on identified as an attractive target for pharmaceutical
intervention. Soon after the identification and characteriza-
tion of farnesyl transferase (FTase) as the enzyme respon-
sible for the first in the series of Ras-modifications, FTase
inhibitors which efficiently blocked Ras mediated cell trans-
formation in cell culture and animal models were devel-
oped [21-23]. However, the results of clinical trials with a
large panel of FTase inhibitors were disappointing and
discouraged many from pursuing further efforts to target
oncogenic Ras. Later, Ras neutralizing antibodies were em-
ployed as oncogenic Ras blockers in cell culture experi-
mentation [24-26] and mutant Ras epitopes were exploited
for their suitability as antigens in the development of
cancer vaccines [27]. Further approaches to target onco-
genic Ras rested on antisense oligonucleotides directed
to the Ras mRNA [28], and more recently on exploiting
structural information and improved in silico approaches
to identify and target druggable pockets or moieties that
affect Ras nucleotide exchange [29,30], Ras activation
[31,32], effector interaction [33,34] or binding to escort
proteins critical for subcellular trafficking [35]. Moreover,
numerous studies have targeted Ras downstream effector
pathways such as Raf kinases, MEK or PI3Ks [36,37].
However, to date, Raf, MEK and PI3K inhibitors have
shown little efficacy in the treatment of oncogenic Ras
driven tumours, essentially evidencing that we still do not
understand all intricacies of Ras signaling in the context
of oncogenesis. In sum, in the light of the high prevalence
of Ras mutations in human tumors it is sobering that 30
years after its discovery as the first human oncogene nostrategy for the direct blockade of oncogenic Ras has
reached clinical use.
In the present study we have developed and characterized
a novel approach for the blockade of Ras-GTP dependent
signaling. We demonstrate that oligovalent, Ras-GTP scav-
enging probes composed of up to 3 wild-type or mutant
RBD modules, behave as “multivalent scavengers of onco-
genic ras” (MSOR) that can be applied to inhibit various
parameters of Ras-dependent oncogenic cell transformation
in an adjustable fashion.
Results
Oligovalent Ras-binding domains block oncogenic
Ras-induced signaling
We have previously employed modular probes consist-
ing of oligomerized Ras-binding domain (RBD) units as
novel Ras-GTP-specific probes. Fused to EGFP, these olig-
omers are instrumental for the visualization of growth
factor-stimulated activation of endogenous Ras in live cells
[38-41]. In the course of those studies we noticed that
oligomeric RBD-variants sequestered Ras-GTP in vitro in
an oligomerization grade-dependent fashion and inter-
fered with Ras-dependent signaling in COS-7 cells [38].
This prompted us to test whether or not RBD-oligomers
can be used to block the action of oncogenic Ras. In the
present study we use the MSOR nomenclature introduced
in ref. [39] which is recapitulated in Figure 1A.
In order to confirm the previously observed inhibitory
effect of MSOR on oncogenic Ras-signaling we com-
pared the impact of mono-, di-and trimeric wildtype
RBDs (E1-R1, E1-R2, E1-R3, respectively) on oncogenic
K-RasG12V induced Erk kinase activation in mouse fibro-
blasts. NIH3T3 cells were transfected with various com-
binations of constitutively active, oncogenic K-RasG12V,
HA-tagged Erk2 and different RBD-expressing plasmids.
As expected, K-RasG12V enhanced activation of the
co-transfected Erk2 kinase (as assessed by Erk2 phos-
phorylation) and this activation was diminished in the
presence of mono- and oligovalent wild-type RBD con-
structs (Figure 1B). Importantly, the blocking efficiency
of RBDs increased as the degree of oligomerization
rose from single (E1-R1) to triple (E1-R3) with the lat-
ter abolishing RasG12V-dependent signaling.
To substantiate this observation and to ascertain the
specificity of the blocking effect, we tested RBD-variants
containing the R59A mutation which lowers the affinity
of RBD for Ras-GTP by about 30fold [14,42]. This type
of mutations is commonly used in the context of full-
length Raf to disrupt Ras-to-Raf signal propagation in cell
biological studies [11]. In line with its inability to interact
with Ras-GTP in vitro [38] the RBD-R59A-monomer E1-
R1(A) did not significantly block Ras-K-RasG12V-induced
phosphorylation of Erk2 (Figure 1B). However, expression




















Figure 1 MSOR inhibit oncogenic Ras-induced signaling. (A) Schematic presentation of the EGFP-fused RBD mono- and oligomers
explored in this study. The different mono- di and trivalent probes (R1, R2, R3) are composed of either wild-type or mutant c-Raf-derived
RBDs. The RBD-mutations R59A (*) and R59A/N64D (**) are abbreviated by (A) and (A/D), respectively. Oligovalent probes consisting of
two or three RBDs are collectively described as MSOR for multivalent scavengers of oncogenic Ras. (B) The influence of RBD monomers
and MSOR on Ras-induced signaling was studied in NIH3T3 cells transiently expressing K-RasG12V, HA-tagged Erk2 and mono-, di- or
trivalent EGFP-RBDs (wild type or R59A-mutant). Cell lysates were subjected to western blot analysis detecting phosphorylated and total Erk2 and
expression of EGFP-RBD-constructs. Signals from four independent experiments were quantified and expressed as ratio of phosphorylated and
total Erk2.
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with gradually increasing strength, albeit always with lower
potency than the wild-type MSOR counterparts. Note-
worthy, E1-R3(A) expression was lower than that of its
monomeric counterpart E1-R1(A), arguing that the grad-
ual increase in blocking strength did not reflect the mere
increase in numbers of RBD modules but rather was con-
tingent on the presence of concatenated RBD units. These
data recapitulated previous findings from COS-7 cells [38],
and illustrated the validity of the oligomerization principle
as a means to raise and tune the avidity and affinity of oli-
govalent binding domains for Ras-GTP.RBD-oligomers inhibit different parameters of Ras-mediated
cellular transformation
Oncogenic Ras-signaling stimulates several pro-tumori
genic pathways that regulate cell proliferation, migration
and invasion, among other events. Given their ability to
inhibit K-RasG12V-signaling, we hypothesized that MSOR
might block aspects of oncogenic Ras-driven trans-
formation. First, we tested the ability of E1-R1 and E1-
R3 to block K-RasG12V-induced invasion in matrigel.
As shown in Figure 2A, both wild-type RBD-variants
interfered with the K-RasG12V-induced invasion of COS-7






Figure 2 MSOR mitigate different parameters associated with cellular transformation. (A) The influence of mono- and trivalent wild-type
RBDs on Ras-driven invasion was analyzed after transient transfection of COS-7 cells with expression constructs for K-RasG12V and E1, E1-R1 or E1-R3
and subsequent transmigration of transfected cells through a Matrigel® layer. The figure shows the average of three independent experiments. (B) The
impact of mono- and trivalent wild-type RBD probes on c-Met-stimulated anchorage-independent growth was investigated by seeding NIH3T3-TM cells
transiently expressing E1, E1-R1 or E1-R3 into soft agar and subsequent culture in the presence or absence of 25 ng/ml NGF. Colony formation was
evaluated by counting of colonies in at least ten arbitrarily selected vision fields. The figure shows the average of three independent experiments.
(C) Effect of the trivalent wild-type RBD construct on the Ki-RasG12V-induced protease gene expression. COS-7 cells were transiently transfected with a
plasmid encoding E1 alone or an expression construct for K-RasG12V along with E1 or E1-R3. The impact of RBD constructs on K-RasG12V-stimulated
expression of different proteases was analyzed on a custome oligonucleotide microarray. Signals were assessed densitometrically and normalized to the
E1 expression level. See Material and methods for a more detailed description. Data are derived from three independent experiments. (D) Consequences
of mono- and trivalent wild-type RBD probes on the K-RasG12V-stimulated induction of the human MMP1-promoter. NIH3T3 cells were transiently
transfected with E1, E1-R1 or E1-R3 together with an expression construct encoding K-RasG12V as indicated. Then, a MMP-1-firefly-luciferase reporter
plasmid was co-transfected along with a reference renilla luciferase construct and the relative luciferase activity was determined. The figure shows the
average of three independent experiments each performed in duplicates.
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anchorage-independent growth, another important hall-
mark of cellular transformation. To this end we chose to
study NIH3T3 cells, since these cells retain numerous fea-
tures of untransformed cells including cell-cell contact in-
hibition or the requirement for substrate attachment for
productive growth and proliferation. However, NIH3T3
cells do not express EGFR, the prototypical receptor tyro-
sine kinase commonly used to robustly activate Ras [43],
but instead express high levels of PDFGR which is a poor
Ras activator. To study Ras signaling in these cells we
employed an engineered subline termed NIH-TM which
responds to stimulation with Nerve Growth Factor (NGF)
owing to the stable expression of a TrkA/c-Met hybrid re-
ceptor composed of the extracellular part of Trk and the
intracellular domain of c-Met [44]. Stimulation of c-Met
activates Ras via the canonical Grb-2/Sos pathway and in-
duces proliferation of NIH3T3 cells [45]. Moreover, over-activation of this receptor tyrosine kinase promotes tumor
growth and metastasis [46]. Accordingly, NGF-treatment
of NIH-TM cells lead to increased colony formation in soft
agar and this effect was completely reversed in the pres-
ence of E1-R1 or E1-R3 (Figure 2B), consistent with the
ability of wild-type RBD-constructs to also block growth
factor-stimulated Ras signaling.
Anchorage-independent growth and cell invasion de-
pend on the action of matrix-degrading enzymes. The pro-
moter region of several protease-encoding genes contains
a Ras-responsive element (RRE) or an RRE-like enhancer
motif [47,48]. Microarray analysis confirmed that onco-
genic K-Ras induced the expression of several protease
genes of the ADAM’s and cathepsin families that act both
intra- and extracellularly and are involved in matrix remod-
eling (Figure 2C, Additional file 1). Importantly, the Ras-
stimulated upregulation of these proteases was abrogated
by E1-R3 (Figure 2C, Additional file 1). Furthermore, this
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of the RRE-containing MMP-1 promoter in NIH3T3 cells,
as assayed using a luciferase reporter system (Figure 2D).
Interestingly, in this case the single RBD unit (E1-R1) was
unable to even partially inhibit the effect of K-RasG12V
(Figure 2D) or H-RasG12V (Additional file 2), highlight-
ing once more the oligomerization dependent, adjustable
blocking potency of MSOR. Moreover, these data suggested
that distinct end points of oncogenic Ras signaling exhibit
varying sensitivities to the action of RBD polypeptides.
MSOR interfere with Ras-dependent cell survival signaling
and induce apoptosis
So far, the impact of MSOR was studied in the context
of oncogenic Ras signaling. However, we noticed previ-
ously that expression of high affinity MSOR in the ab-
sence of constitutively active Ras has a profound effect
on the morphology and viability of various types of cells
[38]. Figure 3A shows fluorescence images of COS-7
cells expressing E1-R1, E1-R2 or E1-R3 in the absence
of Ras co-transfection. Whereas expression of E1-R1 had
no obvious effect on morphology and overall appearance
of COS-7 cells, expression of the more avid MSOR vari-
ants E1-R2 and E1-R3 induced dramatic changes in cell
morphology giving rise to spindle-like and asymmetric
shapes, fragmented nuclei, vacuoles and membrane bleb-




Figure 3 Targeting endogenously active Ras by MSOR impacts on cel
EGFP or mono-, di- or trivalent wild-type RBD probes. Scale bar 10 μm. (B)
was determined by measuring Annexin V-positive cells using FACS and no
independent experiments. (C) Caspase gene expression in COS-7 cells, tran
with E1 or E1-R3 was analyzed on a custom oligonucleotide microarray. Sig
expression level. See Material and methods for a more detailed description
and methods for a more detailed description.Since membrane blebbing and other phenotypic changes
in cells expressing E1-R3 were reminiscent of apoptotic
cells we investigated whether or not MSOR induced apop-
tosis of cells expressing native wild-type Ras. Annexin V-
staining confirmed the increased occurrence of apoptosis
among MSOR-transfected COS-7 cells (Figure 3B). These
data are compatible with a MSOR-mediated blockade of
basal, endogenous Ras-GTP signaling, which reportedly
protects cells from apoptosis [49]. This notion was further
supported by microarray data showing that E3-R3 upreg-
ulated the expression of caspases (Figure 3C, Additional
file 1), even so in the presence of co-transfected oncogenic
Ras. Importantly, the higher potency of E1-R3 versus E1-
R1 in apoptosis induction was not a result of an overall
higher total number of RBD units but caused by the pres-
ence of the oligovalent polypeptides, because cells express-
ing up to 5 fold higher levels of E1-R1 did not exhibit the
same signs of cellular breakdown (unpublished observa-
tion). We concluded from these findings that MSOR im-
pair cell survival by the sustained strong sequestration and
blockade of basal Ras-GTP signaling.
Adjusted inhibition of Ras-mediated cellular effects by
inducible MSOR expression
The cytotoxic effects of E1-R2 and E1-R3 prompted us to
develop strategies that allowed tuning the action of MSOR.
First, we employed a tetracycline controllable systemE1-R3 E1-R3
l survival. (A) Confocal images of Cos-7 cells transiently expressing
The fraction of dead cells among E1-, E1-R1- or E1-R3-expressing cells
rmalized to the EGFP-expressing condition. Data represent three
siently transfected with an expression construct for K-RasG12V along
nals were assessed densitometrically and normalized to the E1
. Data are derived from three independent experiments. See Material
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MSOR like E1-R3. COS-7 cells were transiently transfected
with Tet-off constructs driving the expression of mono-
meric E1-R1 and trimeric E1-R3. In a non-repressed
setting, expression of E1-R1 and E1-R3 was readily de-
tectable (Figure 4A) but did not induce the prominent
morphological changes observed under conditions of en-
hanced expression (Figure 3A). Addition of increasing
concentrations of the tetracycline-derivative doxycycline
(Dox) to the culture medium inhibited the MSOR expres-
sion in a concentration-dependent manner (Figure 4A),
thus confirming the proper function of the inducible ex-
pression system.
Next, the effect of experimentally induced expres-
sion of RBD-constructs on the RasG12V-stimulated Erk2-
activation in COS-7 was assessed (Figure 4B). Induction
of E1-R3 expression decreased RasG12V-sparked Erk2-
phosphorylation while the corresponding monomer was
ineffective under the same conditions. This finding con-
trasts with the blocking action of E1-R1 in transient over-
expression experiments (see Figure 1B) and suggested that
MSOR-dependent blockade of distinct Ras elicited effects
may depend on the expression levels achieved in individ-
ual experiments and/or may sometimes require sustained
action of the MSOR proteins over a longer period of time.
In agreement with its blocking of Erk2 activation, the
wild-type trimer but not the monomer was able to blunt
RasG12V-stimulated activation of the MMP-1-reporter
in NIH3T3 cells (Figure 4C) and EGF-driven invasion of
COS-7 cells (Figure 4D).
Taken together these data illustrate the efficacy of in-
ducible MSOR to control and tune Ras action.
Controlled inhibition of oncogenic Ras by attenuated MSOR
Another potential approach for reducing the cytotoxicity
of MSOR constructs was the introduction of specific mu-
tations in the RBD that strongly decrease their affinity for
Ras-GTP, like the R59A mutation described above. This
approach was successfully applied previously, and lead to
the development of the double point mutant RBD-R59A/
N64D, which in its trimeric form E1-R3(A/D) retained
high avidity for Ras-GTP while exhibiting little cytotox-
icity [38,39].
In line with those features, over-expression of E1-R3
(A/D) or its monomeric counterpart E1-R1(A/D) in COS-7
cells did not induce morphological changes or apoptosis
(Figure 5A) as observed with the wild-type MSOR E1-R3
(Figure 3A). Similarly to E1-R1(A), the E1-R1(A/D) mono-
mer did not impact on oncogenic K-Ras-driven signal
transduction (Figure 5B). However, the trivalent double
point mutant E1-R3(A/D) clearly diminished the RasG12V-
induced Erk2-activation in both COS-7 and NIH3T3 cells
(Figure 5B). Moreover, E1-R3(A/D) did also abrogate as-
pects of cellular transformation such as MMP1-activation(Figure 5C) and cell invasion (Figure 5D). Collectively, these
findings illustrated that even low-affinity, biologically inert
modules like the double point mutant RBD-R59A/N64D
can be converted into robust scavengers of oncogenic Ras
by increasing their avidity for Ras-GTP via oligomerization.
Discussion
This study describes a novel application for the RBD of
c-Raf as a building block of multivalent probes for the
adjustable and graded inhibition of oncogenic Ras signal-
ing. The data presented herein illustrate that MSOR are
able to specifically target and block various events down-
stream of aberrant Ras-signaling including Erk-activation
(Figures 1B and 5B), induction of matrix-remodeling en-
zymes (Figures 2C, 2D and 5C), Ras-stimulated matrix in-
vasion (Figures 2A and 5D) and growth factor-induced
contact-independent growth (Figure 2B). Moreover, it is
worth emphasizing that MSOR not only counteracted the
action of oncogenic Ras itself but also abrogated several
parameters of cellular transformation sparked by cell sur-
face growth factor receptors that signal via Ras (Figures 2B
and 4D), suggesting a potentially broader application of
MSOR in pro-tumorigenic settings that involve aberrant
Ras-signaling. Importantly, the binding properties of MSOR
are amenable to manipulation at three different levels: 1st,
by varying their oligomerization grade and thus the avidity
towards Ras-GTP [38], 2nd, by introducing point mutations
in single RBD modules, affecting the affinity of individual
RBDs to Ras-GTP and 3rd by regulating their protein ex-
pression levels. Several observations reported here strongly
indicate that different combinations of the three parameters
enumerated above will generate MSOR with distinct bind-
ing and inhibitory properties. For example, the wild-type
RBD-monomer R1 effectively blocked different aspects
of enhanced Ras-signaling (Figures 1B, 2A and 2B) when
over-expressed to high levels in cells but it was ineffective
at low expression levels in most cell types studied (Figure 4).
In contrast, the trivalent protein R3 exhibited strong inhibi-
tory effect in the same settings irrespective of its expression
levels, suggesting that a higher avidity for Ras-GTP effect-
ively increases the blocking potency and essentially com-
pensates for low expression levels.
Along the same lines, we observed that one and the
same RBD probe exhibits variable potencies for blocking
different events downstream of oncogenic Ras. For in-
stance, the monovalent wild-type unit R1 does not even
partially affect matrix metalloproteinase induction by Ras
G12V, even though it does impinge on proximal Ras effec-
tors like Erk in essentially the same system. The simplest
explanation for this and related observations is that dis-
tinct cell biological readouts of oncogenic Ras require the
action of different Ras effector pathways, or combinations
thereof, that are distinctively sensitive to MSOR action.








Figure 4 Adjusted, low-level expressed MSOR maintain their Ras-blocking activity. (A) Tet-off promoter-controlled expression of
RBD-monomers and MSOR. COS-7 cells were transfected with pNRTIS 12-derived plasmids encoding E1-R3 and subsequently left untreated or treated
with different concentrations of doxycycline (Dox) to modulate MSOR expression levels. (B) The impact of inducible mono- and trivalent wild-type RBD
probes on oncogenic Ras-stimulated MAP-kinase signaling. COS-7 cells were transiently transfected with different constructs as indicated. Next, cells
were divided into samples that were grown either in the absence (-) or presence (+) of 100 ng/ml Dox. Cells lysates were analyzed by Western blot
detecting phosphorylated and total Erk2 and the expression of EGFP-constructs. One representative experiment out of three independent experiments
is shown. (C) Influence of inducible mono- and trivalent wild-type RBD probes on oncogenic Ras-stimulated MMP-1 promoter activation. NIH3T3 cells
were transiently transfected with the MMP-1-luciferase reporter, the K-RasG12V-encoding construct and Tet-off-controlled EGFP-constructs E1, E1-R1 or
E1-R3. Expression of EGFP-constructs was turned on (-Dox) or off (+100 ng/ml Dox) and reporter gene activity was measured. The figure shows the
average result from three independent experiments each performed in triplicate. (D) Influence of inducible mono- and trivalent wild-type RBD probes
on EGF-stimulated cell invasion. COS-7 cells were transfected with the Tet-off-regulated EGFP-constructs indicated, and cultured in the absence of Dox.
Subsequently, EGFP-expressing cells were collected by preparative fluorescence activated cell sorting and cultured in absence or presence of 100 ng/
ml Dox to regulate the expression of E1, E1-R1 and E1-R3. Then cells were collected, seeded onto Matrigel-coated Transwells and subjected to invasion
in absence or presence of 50 ng/ml EGF. Results represent the means of two entirely independent experiments.
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thermodynamic affinities for Ras-GTP of up to two orders
of magnitude [50]. Taking into account that many other
parameters such as steric considerations or subcellular
compartmentalization aspects can additionally regulate
Ras/effector coupling in vivo, it is well conceivable thatthe engagement of different effectors by oncogenic Ras
may be distinctively sensitive to MSOR action. Indeed, in
the mentioned case of MMP-1 regulation by oncogenic
Ras, available evidence suggest that MMP-1 expression
requires other Ras-sparked signals in addition to Erk,










Figure 5 A non-toxic MSOR-variant efficiently blocks Ras-induced signaling and transformation. (A) Confocal images of COS-7 cells transiently
expressing the mono- and trivalent low affinity RBD-R59A/N64D probes (left panel). Scale bar 10 μm. Cell death analysis of COS-7 cells transiently
expressing E1, E1-R1(A/D) or E1-R3(A/D) using Annexin V-staining (right panel). The average of three independent experiments is shown. (B) Quantitative
assessment of Western blot analysis of oncogenic Ras-induced Erk2 activation. NIH3T3 (left panel) and COS-7 (right panel) cells transiently expressing
K-RasG12V, HA-tagged Erk2 and E1, E1-R1(A/D) or E1-R3(A/D) were subjected to western blot analysis detecting phosphorylated and total Erk2. Signals
were quantified and expressed as ratio of phosphorylated and total Erk2. The ratios derived from the different conditions were normalized to EGFP, and
the average of three independent experiments is shown in the figure. (C) Impact of low-affinity RBD constructs on the K-RasG12V-stimulated induction
of the human MMP1-promoter. NIH3T3 cells were transiently transfected with the different RBD-constructs indicated. Then, a MMP-1-firefly-luciferase
reporter plasmid was co-transfected along with a reference renilla luciferase construct and the relative luciferase activity was determined after 24 h. The
figure shows the result of three independent experiments each performed in duplicate. (D) Influence of the low-affinity RBD probes on the oncogenic
Ras-stimulated invasiveness of COS-7 in a Matrigel-coated Transwell assay. The data depicted show the average from three independent experiments.
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pathway like the Raf/MEK/Erk cascade may not suffice to
compromise all-or-nothing, switch-like type of threshold-
controlled processes [52,53]. Furthermore the final outcome
to Ras/Erk pathway activation is subject to regulation by
intrincate, as yet not fully understood positive and negative
feedback loops [54-56] that may add further levels ofcomplexity in settings of incomplete Ras-GTP blockade by
MSOR. Taken together, these considerations indicate that
the degree of MSOR-mediated inhibition of a proximal
downstream effector of Ras such as Erk, will not necessarily
translate into the same degree of inhibition of a given Ras-
dependent tumorigenic hallmark. At the same time, from a
methodological point of view, these considerations indicate
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can be instrumental tools for delineating the regulatory and
mechanistic properties of the signaling network down-
stream of Ras.
As mentioned before, the affinity of the individual
RBD modules for Ras-GTP is one major parameter that
allows adjusting the strength of binding and inhibition.
Many RBD point mutants have been described and exten-
sively characterized biochemically and structurally with re-
gard to their interaction with Ras-GTP. For example,
replacing arginine 59 for alanine in RBD yields a polypep-
tide with 29-fold diminished affinity for Ras-GTP, and in-
corporation of a second mutation (N64D) further reduces
affinity by a factor of four [14,16]. In agreement with those
properties, the single R59A and double R59A/N64D mu-
tants did not block any of the investigated Ras effects if
applied in their monomeric forms (R1(A) and R1(A/D))
but they did inhibit Ras-GTP signaling at all investigated
levels once converted to their trivalent counterparts R3(A)
and R3(A/D) (Figures 1 and 5). This was a striking obser-
vation since it evidenced that even RBD mutants deemed
to be biologically inert due to negligible Ras-GTP binding
could turn into potent Ras blockers if rendered more avid
towards Ras-GTP by oligomerization. These consider-
ations gain further relevance in the light of recent insights
into the Ras-dependent activation mechanism of Raf. A
wealth of experimental data has recently established that
Raf kinases function as homo- and heterodimers [57-60].
Although many details of Raf regulation remain obscure it
is evident that only the dimeric form is responsive and
sensitive to activation by Ras-GTP [57]. Thus, the oligo-
meric RBD-based units, as used in the present study may,
in essence, reflect and recapitulate aspects of the physio-
logical interaction of Ras-GTP with a Raf dimer.
Aberrant Ras activity due to oncogenic mutations is
found with high frequency in different human malignan-
cies and remains one of the most attractive molecular
targets for rational cancer treatment [15]. Although dif-
ferent approaches such as DNA vaccination, microRNA
targeting Ras and farnesyl-transferase inhibition have
been exploited as putative therapeutic strategies to block
oncogenic Ras, they have all not stood the test of time
and clinical trials [61]. More recently, various novel
structure-guided approaches for targeting oncogenic Ras
have been described [29,33,35]. Of note, others have previ-
ously exploited the single RBD from c-Raf-1 or other Ras-
GTP interacting protein modules in order to suppress
oncogenic Ras-induced cell transformation in various ex-
perimental settings [62,63]. The MSOR approach described
here adds to this panel of Ras inhibitory strategies. As a
unique feature, MSOR are amenable to fine-tuning for ad-
justment of their inhibitory strength. Their potent effect on
different parameters of Ras-stimulated cellular transform-
ation in vitro (Figures 2, 4 and 5) provides a solid basis forfurther studies investigating the performance of MSOR in
the context of in vivo tumor growth and progression. How-
ever, being genetically encoded, the use of MSOR for treat-
ment of Ras-dependent tumours must await improved gene
delivery protocols. Alternatively, however, MSOR could po-
tentially be delivered via alternative routes, taking advantage
of specific features of Ras-driven tumours. For example,
Ras-positive tumours exhibit strongly enhanced macropino-
cytosis [64], a property that could be exploited to selectively
deliver polypeptides, nanoparticles or other types of drugs
into the tumour cells.
Conclusions
The data presented herein introduce the multivalent scav-
engers of oncogenic Ras (MSOR) that can be applied as
versatile, adjustable Ras-GTP selective probes. MSOR rep-
resent novel tools to potently inhibit the action of onco-
genic Ras and can be employed in basic research studies of




COS-7 cells and NIH3T3 cells were obtained from the DS
MZ (German Collection of Microorganisms and Cell Cul-
tures, Braunschweig, Germany) and cultured in DMEM
medium supplemented with 10% FCS and 100 μg/ml Gen-
tamycin. Transfection of COS-7 and NIH3T3 cells with
plasmid DNA was performed with NucleofectionR employ-
ing a NucleofectorR device, “Solution V” and “Program
A24” according to directions of the manufacturer (Lonza,
Cologne, Germany) or using the Polyfect™ transfection re-
agent following the directions of the manufacturer (Qiagen,
Hilden, Germany).
DNA constructs
Expression constructs for EGFP-fused RBD-mono- and
oligomers based on the EGFP-C2 vector (Clontech, Moun-
tain View, CA, USA) as well as plasmids encoding con-
stitutively active RasG12V mutants and HA-tagged Erk2
have been described previously [38,39]. Inducible expres-
sion constructs for EGFP and EGFP-MSOR were generated
on the basis of the bicistronic Tet-off vector pNRTIS-21
[38]. cDNAs encoding EGFP and EGFP-RBD fusions
were subcloned as EcoRI/NotI fragment into pNRTIS-21
by standard molecular biology procedures. The luciferase
reporter gene plasmid containing the human MMP-1 pro-
moter has been described previously [65].
Inducible MSOR expression
COS-7 cells were transiently transfected with constructs
encoding inducible, EGFP, mono- or oligovalent EGFP-
RBD probes. Expression of these constructs was induced
or repressed by culturing the cells in absence or presence
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croscopy demonstrated that the expression of EGFP-
constructs was efficiently suppressed in cultures exposed
to Doxycyclin for 72 h.Fluorescence microscopy
Visualization of EGFP fluorescence was performed with
an Axiovert 135 M fluorescence microscope (Carl Zeiss
GmbH, Jena, Germany).Western blot analysis
Western blot analysis of cell lysates for protein expres-
sion and/or protein phosphorylation has been previously
described in detail [38].Luciferase reporter gene assay
5 × 105 NIH3T3 cells were grown in six-well plates
(Greiner, Frickenhausen, Germany) in 2 ml DMEM/10%
FCS to 80–90% confluency. Cells were transferred to
1 ml of fresh medium and transfected with plasmids en-
coding oncogenic Ras and EGFP-coupled RBD-probes.
The next day, cells were transfected simultaneously with
1 μg firefly luciferase-coupled MMP-1-promoter construct,
MMP-1-2G/pGL3 [65] and 0.1 μg pRL-TK plasmid encod-
ing renilla luciferase (Promega, Madison, WI). 14 h post
transfection, cells were harvested using “reporter lysis buf-
fer” (Promega). Firefly and renilla luciferase activities were
determined using the Dual-Luciferase Reporter Assay Sys-
tem kit (Promega, Madison, WI, USA) following the man-
ufacturer’s instructions. Luminescence was measured using
the Promega GLOMAXR 96 Luminometer and reported as
relative light units. Relative MMP-1-promoter activation
was derived by normalizing the firefly luciferase activity to
renilla luciferase activity.Soft agar colony formation assay
The soft agar assay to analyze the anchorage independent
growth of NIH3T3-TM cells was performed as described
before [44]. Briefly, NIH3T3-TM cells, were transfected
with constructs encoding EGFP or EGFP-RBD probes.
Subsequently, 2 × 104 transfected cells were suspended in
0.5 ml DMEM/10% FCS supplemented with 0.4% Seapla-
que agarose and seeded per well of a 24-well tissue culture
plate (Greiner) on a layer of 0.5 ml DMEM/0.8% Seapla-
que agarose. Cultures were fed with 0.2 ml of DMEM/
10% FCS in the presence or absence of 25 ng/ml NGF
every 3 days for 2 weeks. Colonies were then stained with
p-iodonitrotetrazolium violet (Sigma, Munich, Germany)
and microscopically inspected. Data are derived from
counting the number of colonies in at least ten arbitrarily
selected vision fields.Protease expression analysis by cDNA arrays
cDNA microarrays of protease and protease inhibitor se-
quences on nylon membranes and the synthesis of digoxi-
genin labeled cDNA have been described previously [66].
Detailed information on the generation of the protease/
protease inhibitor probes, their arrangement on the mem-
branes as well as experimental details have been published
[67]. In brief, cDNA prepared from COS-7 cells was
digoxigenin-labeled and hybridized on a custom oligo-
nucleotide microarray comprising housekeeping genes,
positive and negative controls, and genes representing a
collection of human intra- and extracellular proteases,
and protease inhibitors. Hybridization patterns were sub-
sequently detected by chemiluminescence and analyzed
using the AIDA imaging software (Raytest, Straubenhardt,
Germany). Average densitometry signals of duplicate spots
from K-RasG12V/E1- and K-RasG12V/E1-R3-xpressing
cells were corrected for the background and normalized
against the respective signal from E1-expressing cells.Cytometric cell analysis and sorting
Cytometric measurements and cell sorting was performed
using a FACS CaliburR instrument (BD Biosciences,
Heidelberg, Germany) equipped with a 488 nm laser
and the CellQuestProR software. For flow cytometric
analysis of EGFP expression, cells transfected with con-
structs encoding EGFP or EGFP-RBD probes were trypsi-
nized and adjusted to a density of 1 × 106/100 μl, forward
scatter (cell size) and sideward scatter (cell granularity) were
determined and vital cells were gated. EGFP signals were
recorded using a 515–545 nm filter and plotted against the
number of events. Sorting of EGFP-positive cells was per-
formed following transfection of 2 × 106 COS-7 cells with
pRNTIS 21-derived expression constructs encoding EGFP
or EGFP-RBD-probes and subsequent cultivation of cells
for 48 h. This procedure routinely yielded an enrichment of
EGFP-expressing cells to approximately 90%.Annexin V staining
COS-7 cells were grown in six-well plates (Greiner) to
80% confluency, transfected the next day with plasmids
encoding EGFP or EGFP-coupled RBD-probes and then
cultured for additional 24 h in fresh culture medium. Cells
were detached by trypsin/versene (Gibco®/Life Technolo-
gies, Darmstadt, Germany) and collected by centrifugation.
The cell pellet was washed twice in 1 × PBS and re-
suspended in 220 μl 1 × bindings buffer (BD Biosciences).
The sample was divided in two: 100 μl sample were
left untreated, the other 100 μl were supplemented
with 2.5 μl Annexin V-APC (BD Biosciences). The dif-
ferent preparations were incubated for 5 min at 37°C
and then for 25 min at room temperature in the dark.
To determine the proportion of dead cells among the
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V-APC was measured using the FACS CaliburR instru-
ment (BD Biosciences) and plotted against EGFP. Subse-
quent propidium iodide (Merck Biosciences, Schwalbach,
Germany) staining revealed that approximately 85% of the
transfected, dead cells underwent apoptosis.
In vitro cell invasion assay
COS-7 invasion was studied using polycarbonate Trans-
wells (Corning Costar Corp., Cambridge, MA, USA) as
previously described [44]. Briefly, cells were cultured
in DMEM supplemented with 10% FCS and, optionally,
100 ng/ml Doxycyclin and/or 50 ng/ml EGF for 72 h.
2 × 105 cells were then seeded onto membrane filters
coated with Matrigel® (BD Biosciences) and transmigra-
tion through the Matrigel® layer was determined after in-
cubation for 24 h. Cell invasion was expressed as the
average number of migrated cells per vision field (100×
magnification) of at least seven, arbitrarily selected vi-
sion fields.
Statistics
All data are expressed as the mean S.E.M. SPSS for
Windows was used for all statistical analyses. The non-
parametric Mann–Whitney (U) test and one-way ANOVA
with Newman-Keuls Multiple Comparisons were used to
analyze if differences among different experimental groups
are statistically significant (p < 0.05).
Additional files
Additional file 1: MSOR inhibit oncogenic Ras-stimulated gene
expression. (A) Representative pictures of a custome oligonucleotide
microarray covering various proteases and integrins that demonstrate
differential effects of the MSOR E1-R3 on K-RasG12V-stimulated gene
expression in COS-7 cells. (B) Graphic presentation of K-RasG12V/E1-regulated
genes that were either induced or repressed compared to E1-expressing
COS-7 cells and counteracted by E1-R3. Up- and down regulation of gene
expression is depicted in green and red, respectively.
Additional file 2: MSOR block oncogenic H-Ras-induced signaling.
NIH3T3 cells were transiently transfected with E1, E1-R1 or E1-R3 together
with an expression construct encoding H-RasG12V as indicated. Subsequently,
plasmids encoding an MMP-1-firefly-luciferase reporter and renilla luciferase
were co-transfected along and the relative luciferase activity was determined.
The figure shows the average of three independent experiments each
performed in duplicates.
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